Clinical implication of HLA class I expression in breast cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Kaneko, Koichi ^a   Ishigami, Sumiya ^a   Kijima, Yuko ^a   Funasako, Yawara ^a   Hirata, Munetsugu ^a   Okumura, Hiroshi ^a   Shinchi, Hiroyuki ^a   Koriyama, Chihaya ^b   Ueno, Shinichi ^a   Yoshinaka, Heiji ^a   Natsugoe, Shoji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Antitumor activity; Hla class i; Survival; T cell immunology

Indexed keywords

HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE FREE INTERVAL; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; TUMOR GROWTH; BREAST TUMOR; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; IMMUNOLOGY; LYMPH NODE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80054707226     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-454     Document Type: Article

References (28)

1. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000, 74:181-273.
2. Tangri S, Ishioka GY, Huang X, Sidney J, Southwood S, Fikes J, Sette A. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 2001, 194:833-846. 10.1084/jem.194.6.833, 2195959, 11560998.
3. Cabrera T, Maleno I, Collado A, Lopez Nevot MA, Tait BD, Garrido F. Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens 2007, 69(Suppl 1):264-268.
4. Nagorsen D, Thiel E. HLA typing demands for peptide-based anti-cancer vaccine. Cancer Immunol Immunother 2008, 57:1903-1910. 10.1007/s00262-008-0493-6, 18317754.
5. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today 1993, 14:491-499. 10.1016/0167-5699(93)90264-L, 8274189.
6. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997, 18:89-95. 10.1016/S0167-5699(96)10075-X, 9057360.
7. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999, 5:178-186. 10.1016/S1357-4310(99)01451-3, 10203751.
8. Eyal A, Levin I, Segal S, Levi I, Klein B, Kuperman O. Variation of HLA-ABC surface antigen expression on adenocarcinoma of the colon in correlation with the degree of differentiation. Nat Immun Cell Growth Regul 1990, 9:222-227.
9. Levin I, Klein T, Goldstein J, Kuperman O, Kanetti J, Klein B. Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival. Cancer 1991, 68:2591-2594. 10.1002/1097-0142(19911215)68:12<2591::AID-CNCR2820681212>3.0.CO;2-L, 1933807.
10. Concha A, Cabrera T, Ruiz-Cabello F, Garrido F. Can the HLA phenotype be used as a prognostic factor in breast carcinomas?. Int J Cancer Suppl 1991, 6:146-154.
11. Petersen BL, Petersen CL, Braendstrup O, Mouritsen S, Engel AM, Svane IM, Werdelin O. Expression of beta 2-microglobulin by premalignant epithelium. APMIS 1993, 101:529-536. 10.1111/j.1699-0463.1993.tb00142.x, 8398092.
12. Pedersen LO, Stryhn A, Holter TL, Etzerodt M, Gerwien J, Nissen MH, Thogersen HC, Buus S. The interaction of beta 2-microglobulin (beta 2 m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2 m. Eur J Immunol 1995, 25:1609-1616. 10.1002/eji.1830250621, 7614989.
13. Cabrera T, Angustias Fernandez M, Sierra A, Garrido A, Herruzo A, Escobedo A, Fabra A, Garrido F. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996, 50:127-134. 10.1016/0198-8859(96)00145-0, 8891736.
14. Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, Nabeta Y, Kimura S, Kaya M, Nagoya S, Wada T, Yamashita T, Sato N. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006, 97:1374-1380. 10.1111/j.1349-7006.2006.00317.x, 16995877.
15. Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H, Nishimura M. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007, 98:1424-1430. 10.1111/j.1349-7006.2007.00558.x, 17645781.
16. Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol 2007, 177:1269-1272. 10.1016/j.juro.2006.11.082, 17382705.
17. Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008, 27:5869-85. 10.1038/onc.2008.273, 2729106, 18836468.
18. de Kruijf EM, Sajet A, van Nes JG, Natanov R, Putter H, Smit VT, Liefers GJ, van den Elsen PJ, van de Velde CJ, Kuppen PJ. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 2010, 185:7452-9. 10.4049/jimmunol.1002629, 21057081.
19. Boomsma MF, Garssen B, Slot E, Berbee M, Berkhof J, Meezenbroek Ede J, Slieker W, Visser A, Meijer S, Beelen RH. Breast cancer surgery-induced immunomodulation. J Surg Oncol 2010, 102(6):640-8. 10.1002/jso.21662, 20677220.
20. de Kruijf EM, van Nes JG, Sajet A, Tummers QR, Putter H, Osanto S, Speetjens FM, Smit VT, Liefers GJ, van de Velde CJ, Kuppen PJ. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 2010, 16:1272-80. 10.1158/1078-0432.CCR-09-1844, 20145162.
21. Lavado-Valenzuela R, Benavides M, Carabantes F, Alonso A, Caballero A. MHC class I chain-related gene A transmembrane polymorphism in Spanish women with breast cancer. Tissue Antigens 2009, 74:46-9. 10.1111/j.1399-0039.2009.01254.x, 19392799.
22. Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Aikou T. HLA-class I expression in gastric cancer. J Surg Oncol 2008, 97:605-608. 10.1002/jso.21029, 18459158.
23. Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991, 51:6372-6380.
24. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005, 117:248-55. 10.1002/ijc.21163, 15900607.
25. Sato N, Hirohashi Y, Tsukahara T, Kikuchi T, Sahara H, Kamiguchi K, Ichimiya S, Tamura Y, Torigoe T. Molecular pathological approaches to human tumor immunology. Pathology International 2009, 59:205-217. 10.1111/j.1440-1827.2009.02353.x, 19351363.
26. Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K, Fujii H. Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer 2008, 99:1462-1467. 10.1038/sj.bjc.6604715, 2579690, 18841157.
27. Zia A, Schildberg FW, Funke I. MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients. Int J Cancer 2001, 93:566-570. 10.1002/ijc.1362, 11477561.
28. Aptsiauri N, Cabrera T, Mendez R, Garcia-Lor A, Ruiz-Cabello F, Garrido F. Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 2007, 601:123-131. 10.1007/978-0-387-72005-0_13, 17712999.